Macter International Limited has successfully launched Hepanox (Enoxaparin Sodium) Pre-filled Syringe (PFS), enhancing its biopharmaceutical portfolio in the anticoagulant segment.
- The launch of Hepanox PFS marks a significant milestone for Macter, strengthening its presence in the therapeutic market.
- Hepanox is classified as a low molecular weight heparin (LMWH) anticoagulant.
- This development reflects Macter's commitment to long-term growth and addressing evolving healthcare needs.